Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVA vs Standard Chemotherapy or VA in High-Risk AML
NCT06810791Phase 3Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of homoharringtonine in acute myeloid leukemia (AML) (4 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Composite Complete Remission. Started Jan 2025; status: recruiting.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06810791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810791.